ArticleNature communications2024
Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
12.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 41 citations in OpenAlex.
- MVA.HIVconsvX vaccination-evoked T cell expansion inversely associates with age in people with HIV-1 on antiretroviral therapy.The Journal of clinical investigation · 2026Trial
- Trial
- Constitutive natural killer cell features associated with post-treatment control of SIV infection in the pVISCONTI study.Nature communications · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- CD8ɑ+ cells suppress SIV replication without the development of mutations within MHC class-I-restricted epitopes during post-treatment control.Journal of virology · 2026Article
- Modulation of pulmonary IL-21 expression during latent TB and M. tuberculosis/SIV coinfection.JCI insight · 2026Article
- AZD5582 robustly reactivates latently infected cells and clears the majority of those reactivated from the SIV reservoir.bioRxiv : the preprint server for biology · 2026Article
- Comparative Evaluation of the New HIV VIDAS® DUO AG/AB Assay With DUO Ultra on Well Characterized Participants From the HIV-1 Acute Infection French ANRS PRIMO Cohort.Journal of medical virology · 2026Article
- The elite controller phenotype.Current opinion in HIV and AIDS · 2026Review
- Recapitulating the qualities of HIV-specific CD8 + T cells from spontaneous controllers.Current opinion in HIV and AIDS · 2026Review
- Nur77 Is Associated With Polyfunctional Properties in Virus-Specific Human CD8European journal of immunology · 2026Article
- A Tissue Virus Microenvironment with Activated Stress Responses Underlies Durable SIV Persistence.bioRxiv : the preprint server for biology · 2026Article
- Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control.Nature immunology · 2026Article
- Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.The Journal of clinical investigation · 2026Article
- Post-treatment SIV control is associated with specific features of viral persistence before and after treatment interruption.Nature communications · 2026Article
- Maintenance of intestinal CX3CR1Nature communications · 2026Article
- Duration of Initial Viremia Modulates Functional Properties of HIV-specific T Cell Receptors.Research square · 2026Article
- Duration of Initial Viremia Modulates Functional Properties of HIV-specific T Cell Receptors.bioRxiv : the preprint server for biology · 2026Article
- Article
- Differential Effect of Cytokines on CD4+ T-Cell Activation, Metabolism, and Susceptibility to HIV-1 Infection.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 1 country.
Caroline PassaesInstitut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, Paris, France. cpereira@pasteur.fr.ORCID 0000-0002-0813-2521
Delphine DesjardinsUniversité Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.ORCID 0000-0002-5820-3914
Anaïs ChapelInstitut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, Paris, France.
Valérie MonceauxInstitut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, Paris, France.ORCID 0000-0002-8599-2146
Julien LemaitreUniversité Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.
Adeline MélardUniversité Paris Cité; INSERM, U1016; CNRS, UMR8104, Paris, France.ORCID 0000-0003-1207-0201
Federico Perdomo-CelisInstitut Pasteur, Université Paris Cité, HIV Inflammation and Persistence Unit, Paris, France.ORCID 0000-0003-0119-8306
Cyril PlanchaisInstitut Pasteur, Université Paris Cité, INSERM U1222, Humoral Immunology Unit, Paris, France.ORCID 0000-0002-5142-7253
Maël GourvèsInstitut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, Paris, France.ORCID 0009-0002-3947-1523
Nastasia DimantUniversité Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.ORCID 0009-0004-3252-4789
Annie DavidInstitut Pasteur, Université Paris Cité, HIV Inflammation and Persistence Unit, Paris, France.
Nathalie Dereuddre-BosquetUniversité Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.ORCID 0000-0001-6682-6313
Aurélie Barrail-TranUniversité Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.ORCID 0000-0002-6053-6275
Hélène GougetUniversité Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.
Céline GuillaumeUniversité Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.
Francis RelouzatUniversité Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.ORCID 0000-0002-6387-8481
Olivier LambotteUniversité Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.
Jérémie GuedjUniversité Paris Cité, IAME, INSERM, F-75018, Paris, France.ORCID 0000-0002-5534-5482
Michaela Müller-TrutwinInstitut Pasteur, Université Paris Cité, HIV Inflammation and Persistence Unit, Paris, France.ORCID 0000-0002-3854-2396
Hugo MouquetInstitut Pasteur, Université Paris Cité, INSERM U1222, Humoral Immunology Unit, Paris, France.ORCID 0000-0002-4230-610X
Christine RouziouxUniversité Paris Cité/APHP Hôpital Necker - Enfants Malades, Paris, France.
Véronique Avettand-FenoëlUniversité Paris Cité; INSERM, U1016; CNRS, UMR8104, Paris, France.ORCID 0000-0002-7022-2990
Roger Le Grand *Université Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.ORCID 0000-0002-4928-4484
Asier Sáez-Cirión *Institut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, Paris, France. asier.saez-cirion@pasteur.fr.ORCID 0000-0003-2406-7536
Inserm · FRInstitut Pasteur · FRDélégation Paris 5 · FRHôpital Necker-Enfants Malades · FR
Funding
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0MNIAID NIH HHS UM1 AI164562
Abstract
HIV remission can be achieved in some people, called post-treatment HIV controllers, after antiretroviral treatment discontinuation. Treatment initiation close to the time of infection was suggested to favor post-treatment control, but the circumstances and mechanisms leading to this outcome remain unclear. Here we evaluate the impact of early (week 4) vs. late (week 24 post-infection) treatment initiation in SIVmac
Indexed as
HIV InfectionsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsAnti-Retroviral AgentsCD8-Positive T-LymphocytesHumansMaleViral LoadAnti-Retroviral Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.